Supporting our results from PBMCs, olaparib induced a significant decrease in PARP1 activity and recovery of NAD+ levels, and it increased cell viability in an acute pancreatitis model and human monocytic lineage cells subjected to oxidative stress. This evidence concerns the gene PARP1 and acute pancreatitis.